BNTX

Several events impacted BioNTech SE's stock price in the past six months. BioNTech reported a significant decline in Q1 2026 revenues and a wider net loss due to lower COVID-19 vaccine sales and heavy R&D spending. The company announced a share repurchase program of up to $1.0 billion over the next twelve months. BioNTech revealed plans to consolidate its manufacturing footprint, expecting approximately €500 million in recurring annual savings by 2029. News emerged that scientists behind the COVID-19 vaccine would be departing BioNTech. BioNTech announced accelerated immuno-oncology investments and a multiplication of pipeline catalysts in 2026. Vaccine stocks, including BioNTech, slid after an FDA official reportedly linked COVID vaccines and heart conditions in young men. Reports surfaced suggesting Pfizer was planning to sell its BioNTech stake. BioNTech announced its Q3 2025 financial results and corporate update.